Genetically [POMC/PCSK1, LEPR, NCOA1(SRC1), or SH2B1] caused MC4R pathway diseases
RYTMRhythm PharmaceuticalsCatalyst overview
Research summary
This catalyst tracks a Phase 3 update for IMCIVREE™ (Setmelanotide) in Genetically [POMC/PCSK1, LEPR, NCOA1(SRC1), or SH2B1] caused MC4R pathway diseases. The expected timing is based on the latest available company guidance and may change.
DAYBREAK & EMANATE trials. 11/4/24- Reported Ph2 data at ObesityWeek®'24. 2/26/25- Enrollment completed. 8/5/25- Topline data in Q1 2026. 11/04/25:- PR No update 02/26/26:- EMANATE Ph3 topline data now guided for March 2026. 03/16/26:- EMANATE Ph3 missed primary endpoints; post hoc showed BMI reduction in POMC/PCSK1 and SRC1; no new safety signals. 05/05/26:- EMANATE Phase 3 miss restated; no new development milestones disclosed. 08/04/26:- POMC/LEPR long-term weight data presentations noted; no new EMANATE milestone disclosed.
Verification
Confirm timing and program details against the company announcement or filing.